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Introduction: Oncostatin M (OSM) has been implicated in the pathophysiology of rheumatoid arthritis (RA)
through its effect on inflammation and joint damage. GSK315234 is a humanised anti-OSM Immunoglobulin G1
(IgG1) monoclonal antibody (mAb). This 3-part study examines the safety, tolerability and efficacy of GSK315234 in
patients with active RA.
Method: This was a 3-part (Parts A, B and C), multicenter study. Part A and Part B were randomised, double-blind,
placebo-controlled, Bayesian adaptive dose finding studies to investigate the safety, tolerability, efficacy,
pharmacokinetics and pharmacodynamics of single (Part A) and 3 repeat (Part B) intravenous infusions of
GSK315234 in patients with active RA on a background of methotrexate (MTX). Part C was a single dose,
randomised, single-blind, placebo-controlled study to assess subcutaneously administered GSK315234 to patients
with active RA on a background of MTX.
Result: The primary endpoint of the study was mean change in DAS28 at Day 28 in Part A and Day 56 in Part B
and C. All patients receiving at least one dose of GSK315234 were included in safety analysis. In Part A, there were
statistically significant differences in DAS28 between 3 mg/kg and placebo at Day 56, 84 and 91. There was also a
statistically significant difference in DAS28 between 0.3 mg/kg, 3 mg/kg and 10 mg/kg, as compared to placebo, at
Day 84. Although these changes were small and occurred late, they supported progression to Part B and C to
determine the therapeutic potential of GSK315234. For Part B, no significant difference was observed between 6
mg/kg and placebo. For Part C, a statistically significant difference in DAS28 was observed at Day 40, Day 84 and
Day 100 between the 500 mg subcutaneous group, as compared to placebo. No significant findings were observed
at any of the time points for EULAR response criteria, ACR20, ACR50 or ACR70. An exploratory analysis of clinical,
pharmacokinetic and pharmacodynamics data suggests the lack of efficacy may be due to moderate binding
affinity and rapid off-rate of GSK315234 as compared to the higher affinity OSM receptor causing a protein carrier
effect prolonging the half life of OSM due to accumulation of the OSM/antibody complex in the serum and
synovial fluid.
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Conclusion: Our data highlighted the importance of binding affinity and off-rate effect of a mAb to fully neutralize
the target and how this may influence its efficacy and potentially worsen disease activity. Using an anti-OSM mAb
with high affinity should test this hypothesis and examine the potential of OSM as a therapeutic target in RA.
Trial registration: ClinicalTrials.gov no: NCT00674635Introduction
Rheumatoid arthritis (RA) is characterized by chronic
inflammation and destruction of articular joints. Joint
damage leads to physical disability. Despite recent ad-
vances in the treatment of RA with early use of metho-
trexate (MTX), a combination of disease modifying
anti-rheumatic drugs (DMARDs) and the introduction
of biologics, fewer than 50% of patients achieved disease
remission [1]. Consequently, the majority of patients
continue to suffer from active disease. As a result, there
is a need for new treatments to address this ongoing
burden of disease.
Cytokines have a major role in causing joint damage.
Oncostatin M (OSM) is a member of the interleukin
(IL)-6 family of secreted cytokines and is present in the
inflamed synovium and blood of patients with RA [2,3].
It is a pleiotropic cytokine with diverse biological func-
tions relevant to all the major aspects of the pathoge-
nesis of RA. These include activation of endothelium
and fibroblasts, stimulation of the inflammatory me-
diator release and proliferation of synovial cells, promo-
tion of angiogenesis, induction of cartilage breakdown
and osteoclastogenesis leading to bone erosion [4-8]. In
animal models of RA, anti-OSM antibody ameliorated
disease activity [9].
GSK315234 is a humanised anti-OSM immunoglobulin
G1 (IgG1) monoclonal antibody (mAb), which was deve-
loped for the treatment of RA. GSK315234 recognises and
functionally blocks an epitope in the Site II region of the
OSM molecule, preventing its interaction with the cell
surface signaling receptor gp130 and consequently all
the biological functions of OSM. Administration of
GSK315234 to patients with active RA was expected to
reduce the signs and symptoms of RA due to the
inflammatory effects of OSM, reduce pannus formation
and synovial cellular infiltrate due to inhibition of
synovial cell proliferation and reduction in angiogenesis
and reduce joint damage due to the destructive effects
of OSM on cartilage and bone.
The aim of this clinical study was to investigate the
safety, tolerability, pharmacokinetics and pharmaco-
dynamics of GSK315234 in RA using Bayesian adaptive
clinical trial design. Traditional parallel group clinical
trial design requires the sample size to be predetermined
and assessments completed in all subjects before data areanalysed. The design is inefficient for phase II dose esca-
lating trials in which low dose treatment groups are un-
likely to show efficacy but many patients have to be
recruited into these groups. Bayesian adaptive clinical trial
design was developed from sequential designs in which
the design can be changed based on knowledge gained
from interim analyses. Adaptive designs allow trials to
start out with a small up-front commitment of sample size
and then extend them if necessary. Such adaptive trial de-
signs can make a range of protocol changes, including
changing the sample size or randomisation fraction and
dropping or adding treatment arm(s). Changing treatment
schedules and sample sizes allows the trial to be adjusted
to maximize efficiency of the trial; historically this created
very large demand on computation, but modern computer
hardware and software have made this feasible.
Methods
This was a three-part (Parts A, B and C), multicentre
study to investigate the safety, tolerability, efficacy,
pharmacokinetics and pharmacodynamics of intrave-
nous (IV) GSK315234 in Parts A and B and subcuta-
neous (SC) GSK315234 in Part C in patients with RA.
Parts A and B were randomised, double-blind, placebo-
controlled, Bayesian adaptive dose-finding studies to in-
vestigate the effect of single (Part A) and three repeat
(Part B) IV infusions of GSK315234 in patients with
active RA on a background of MTX. Part C was a single
dose, randomised, single-blind, placebo-controlled study
of SC administered GSK315234 in patients with active RA
on a background of MTX.
Patients
Patients between 18 and 75 years of age, who fulfill 1987
American College of Rheumatology (ACR) classification
criteria of RA were recruited [10]. They must have had
active disease: Disease Activity Score 28 (DAS28) of >4.2
at screening and a pre-dose C-reactive protein (CRP) level
of ≥0.5 mg/dl or an erythrocyte sedimentation rate (ESR)
level ≥28 mm/hour at screening and pre-dose. Patients
should have received at least three months of MTX and
have been on a stable dose (up to 25 mg/week) for at least
eight weeks prior to screening and be willing to remain on
this dose throughout the study. Concomitant sulfasalazine
or anti-malarial was permissible if it was taken in addition
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for sulfasalazine and three months for anti-malarial
prior to screening. Other DMARDs must have been
withdrawn for more than one month prior to screening.
Other oral anti-rheumatic therapies, such as non-
steroidal anti-inflammatory drugs (NSAIDs), COX-2 in-
hibitors, oral glucocorticoids, were permitted providing
the dose is ≤10mg/day of prednisolone (or equivalent)
and stable for at least four weeks prior to screening and
remains unchanged through the study. Patients must
use acceptable contraception during the course of the
study. Patients were excluded if they had received prior
biologic therapy, have active infection, previous expo-
sure or past infection caused by Mycobacterium tubercu-
losis, positive Hepatitis B surface antigen or Hepatitis C
antibody result at screening, history of HIV or other im-
munodeficiency disease, history of malignancy, except for
adequately treated non-invasive cancers of the skin (basal
or squamous cell) or carcinoma in situ of the uterine
cervix, positive pregnancy test, elevated liver function tests
on more than one occasion: transaminases or alkaline
phosphatase >3 times the upper limit of normal (ULN) or
total bilirubin >1.5 times ULN, or any significant medical
conditions. Patients with haemoglobin (Hb) <10 g/dl or
platelet count <150 × 109/l were also excluded.
The study was approved by Institution Review Boards
(Serbia: Institute of Rhematology Belgrade, Institute for
Prevention and Treatment and Rehabilitation of Rheu-
matic and Cardiovascular Diseases Belgrade; Ukraine:
Zaporizhzhya State Medical University, Keiv National
Medical University, National Scientific Center, Institute
Kiev, Keiv National Medical University, Donetsk State
Medical University, Lviv National Medical University;
New Zealand: Waikato Hospital, Hamilton, Christ-
church Clinical Studies Trust Christchurch, P3 Research
Wellington; Russia: State Research Institute Novosibirsk,
Yaroslavi Regional Clinical Hospital, Yaroslavi; Smolensk
Regional Clinical Hospital, Moscow Regional Research
Clinical Institute Rhematology Institute Moscow;
Australia: Nucleus Network Melbourne, Austin Center
for Clinical Studies Heidelberg, Princess Alexandra
Hospital Wooloongabba) and Charing Cross Research
Ethics Committee, UK and registered (ClinicalTrials.
gov no: NCT00674635). All patients gave signed
informed consent. The study was conducted in accor-
dance with the guiding principles of the Declaration of
Helsinki.
Dosing and study design
In Part A, initially, six cohorts of eight patients each were
enrolled (Cohorts 1 through 6). After the first interim ana-
lysis, an additional two cohorts of patients were enrolled
(Cohort 7 and Cohort 8). Eligible patients within each
cohort were randomized to GSK315234 (n = 6) or placebo(n = 2). A starting dose of 0.03 mg/kg GSK315234 was
identified, and a Bayesian adaptive dose-finding algorithm
based on a measure of clinical response (weighted mean
DAS28) on Day 14 post-dose was used to identify subse-
quent doses that provided 90% of maximal benefit based
on trial simulation of the Bayesian adaptive pharmaco-
kinetics and pharmacodynamics (PK/PD) design. Patients
in Cohorts 1 through 6 received 0.03 mg/kg, 0.3 mg/kg,
3 mg/kg (2 cohorts of patients were enrolled at this dose
level), 10 mg/kg and 30 mg/kg of GSK315234; doses were
administered in a dose rising fashion. Cohorts 2 through 6
were dosed a minimum of three weeks after dosing of the
last patient in the previous cohort. Cohorts 7 and 8
enrolled simultaneously, and patients received 10 mg/kg
or 20 mg/kg GSK315234.
Part B was a randomized, double-blind, placebo-
controlled, repeat dose study based on changes in DAS28
and PK in Part A. Prior to administration of the first dose,
eligible patients (n = 54) were randomized in a 2:1 ratio to
receive GSK315234 (n = 37) or placebo (n = 17). For each
patient, doses were administered approximately four weeks
apart.
In Parts A and B, GSK315234 or placebo was adminis-
tered by slow IV infusion over two hours.
Part C was a randomized, single-blind, placebo-
controlled, single SC dose study. Eligible patients (n = 17)
were randomized on a 3:1 basis to GSK315234A (n = 12)
or placebo (n = 5). One patient in the placebo arm was
randomized and dosed but was withdrawn as the DAS28
score was lower than 4.2 at pre-dose on day 1. Patients
were administered 500 mg of GSK315234 or matching
placebo as five SC injections of 1 mL each (multiple injec-
tions were needed to administer the full dose). SC injec-
tions were administered on the abdomen, rotating sites
around the umbilicus.
A central randomization schedule generated using the
GSK Randall system was used in all parts of the study.
There is no stratification of sites or countries.
GSK315234 or placebo was administered in a blinded
fashion so that both patients and investigators remained
blinded to treatment allocation.
Assessments
The primary efficacy endpoint was the DAS28 [11]
response rate on Day 28 in Part A and Day 56 in Parts B
and C. Secondary endpoints were ACR [12] and European
League Against Rheumatism (EULAR) response rates
[13], together with Outcome Measure in Rheumatology
(OMERACT) core component measures [14]: tender/
painful count; swollen joint count; Patient’s Assessment of
Arthritis Pain (100 mm visual analogue scale (VAS));
Patient’s and Physician’s Global Assessments of Arthritis
(100 mm VAS); Health Assessment Questionnaire-
Disability Index (HAQ-DI) [15] and Multi-dimensional
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sures included CRP and ESR.
Safety assessments including adverse events (AEs), vital
signs, electrocardiograms and clinical laboratory tests
(haematology, biochemistry and urinalysis) were carried
out at each study visit.
Pharmacokinetics and pharmacodynamics
PD biomarkers after single and repeat IV doses included,
but were not limited to, serum OSM and GSK315234A-
OSM complexes. Immunogenicity was measured by hu-
man anti-GSK315234A antibodies.
Sample size estimation and sensitivity
In Part A, the use of a non-linear mixed effects proce-
dure required simulation techniques to estimate power
for a given sample size and expected magnitude of effect.
Trial simulations of the Bayesian adaptive PK/PD design
using a nonlinear PK/PD model were conducted using
typical parameter estimates that six cohorts of eight pa-
tients each would provide power in excess of 95% to
detect a PK/PD maximum effect value of 66% inhibition
from baseline. The probability of a false positive under
the null hypothesis was approximately 5%. When the
number of cohorts was increased to eight, the power in-
creased marginally accompanied by a steeper cumulative
distribution curve. When the magnitude of response was
33%, the power reduced to 80%. If the response to
GSK315234 had a slower onset but similar sized re-
sponse to adalimumab, the power for the PK/PD analysis
was 80%. Overall, a sample size of 48 (six cohorts) or 64
(eight cohorts) would provide at least 80% power assu-
ming a similar response to adalimumab.
In Part B, a maximum of 54 patients was planned for
enrollment. A treatment difference of 0.95 between the
selected dose and placebo in DAS28 scores 56 days post
dose could be detected with approximately 90% power
based on preliminary estimates of between subject vari-
ability of DAS28 scores seen in the interim analysis of
Part A. This assumes a standard deviation of 1.15 in the
GSK315234 dose group and 1.25 in the placebo dose
group, a two-sided test and an overall alpha of 5%.
In Part C, no statistical techniques were used to deter-
mine the sample size.
Statistical analysis plan
A repeated measure analysis using a mixed effect model
was used, including treatment, visit, and treatment by
visit interaction as fixed effects and patient as a random
effect to analyse the primary efficacy endpoint (mean
change from baseline in DAS28 scores at Day 28). Other
effects such as baseline, baseline by visit, country, gen-
der, age and baseline OSM level were fitted into the
model when deemed necessary.A Bayesian normal dynamic linear model was applied
to DAS28 data of evaluable patients to estimate the
dose–response relationship at Day 28, Day 56, and Day
84 in Part A.
Descriptive statistical methods were used to summarize
all primary and secondary efficacy variables (absolute
value and change from baseline). Significance tests were
carried out at the 2-sided 5% level. Changes from baseline
in tender joint count, swollen joint count, patient’s pain
assessment, patient’s and physician’s global assessment,
CRP, ESR, HAQ-DI and MAF were compared between
treatment groups. If the assumption of normality was not
satisfied for these data, then the data were transformed
prior to analysis.
Weighted mean DAS28 score
The weighted DAS28 was defined by the area under the
curve (AUC) divided by the number of days. The weighted
mean DAS28 was calculated and summary statistics are
presented for Parts A, B and C. The difference in the
mean of the two treatment groups is presented together
with the corresponding 2-sided 95% confidence interval
and the 2-sided P-value.
For EULAR, ACR20, ACR50 and ACR70 response
rates, the Cochran Mantel Haenszel (CMH) test was
used for comparing the responder rates at each visit for
GSK315234A versus placebo stratified by subgroup
factors.Results
In total, 135 patients with RA were dosed (64 in Part A,
54 in Part B and 17 in Part C). Their demographic details
are given in Table 1. All patients in Part A completed the
study. Three patients in Part B withdrew due to lack of
efficacy, investigator discretion and patient withdrawing
consent. One patient in Part C who received one dose of
treatment had to be withdrawn from the study and ana-
lysis due to protocol violation (Figure 1).Efficacy
In Part A, there was a statistically significant difference
in DAS28 between 3 mg/kg and placebo (adjusted mean
difference was −0.71, P <0.05) at Days 56, 84 and 91.
There was a statistically significant difference between
0.3 mg/kg, 3 mg/kg and 10 mg/kg compared to placebo,
at Day 84. The largest adjusted mean change in DAS28
from baseline was observed for the 3 mg/kg group at
Day 84 (adjusted mean change = −1.95 (P <0.05) and the
difference, compared to placebo, was −1.43 (P <0.05).
For Part B, no significant difference was observed bet-
ween 6 mg/kg and placebo. For Part C, a statistically sig-
nificant difference was observed at Days 40, 84 and 100
between the 500 mg SC group compared to placebo.
Table 1 Demographic details of the patients















6 mg/kg 500 mg Placebo
Number of patients randomized 3 1 8 12 12 6 6 37 12 38a











Female: (%) 3 (100) 1 (100) 5 (63) 9 (75) 5 (42) 4 (67) 4 (7) 23 (62) 10 (83) 35 (92)
Male: (%) 3 (37) 3 (25) 7 (58) 2 (33) 2 (33) 14 (38) 2 (17) 3 (8)
BMI in kg/mb, Mean (SD) 28.0 (3.6) 25.7 27.1 (3.9) 24.8(3.1) 25.2(2.8) 28.3 (3.9) 25.3 (5.8) 26.4 (3.5) 27.9(5.1) 27.5 (4.4)
Disease Duration in years, Mean
(SD)




8.0 (6.9) 8.92 (7.8) 8.0 (7.7)
Number of Prior DMARDs, Mean
(SD)
3 (0) 2 2.4 (0.5) 2.7 (0.8) 2.5 (0.7) 3.3 (1.5) 2.7 (1.2) 2.4 (0.7) 2.2 (0.6) 2.4 (0.7)
Rheumatoid Factor Positive N (%) 2 (66) 1 (100) 8 (100) 10 (83) 7 (58) 6 (100) 6 (100) 31 (84) 12 (100) 31 (82)
Anti-CCP antibodies positive N
(%)
22(67) 1 (100) 8 (100) 9 (75) 10 (83) 6 (100) 6 (100) NA NA 12 (75)
Baseline DAS28ESR, Median 5.87 6.77 6.47 6.66 6.15 6.91 6.59 6.43 6.40 6.19
aOne patient in the placebo group was randomized and dosed but excluded from the analysis of efficacy because of ineligible DAS28 score (<4.2) pre-dose on
day 1; bData missing from 1 patient. BMI, body mass index: DAS28, Disease Activity Score 28; DMARDs, disease modifying anti-rheumatic drugs, SD,
standard deviation.
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A, B and C.
No significant findings were observed at any of the
time points for EULAR response criteria, DAS28 remis-
sion, ACR20, ACR50 or ACR70.
For swollen joint count, a statistically significant bene-
fit for the comparison of GSK315234 versus placebo was























Figure 1 Patient disposition.groups at various time points in Part A. There was no
statistically significant improvement of 6 mg/kg over pla-
cebo at any time point in Part B.
No statistically significant improvement in HAQ-DI
compared to placebo was observed at any time point for
all treatment groups (Parts A, B and C).
For both ESR and CRP, there was no statistically
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DAS28 Mean Change From Pre-dose - Part A
Placebo(n=16) 0.03 mg/kg(n=4) 0.3 mg/kg(n=8)
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DAS28 Mean Change From Pre-dose - Part C
Placebo(n=5) 500 mg(n=12)
Figure 2 Mean changes in Disease Activity Score 28 (DAS28) in Parts A, B and C.
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in Parts A, B and C.
For the global fatigue index measured by the MAF,
there was a statistically significant improvement in the
10 mg/kg dose group in Part A compared to placebo at
Day 7 (P = 0.0216). There were no other statistically sig-
nificant changes in GSK315234 dose groups compared
to placebo for any other time point for all treatment
groups.
Safety
Single and repeat doses of GSK315234 were generally
well tolerated. AEs were reported in 48% of the patients
administered GSK315234 (in any part and dose level)
and 32% of the pooled placebo patients (Table 2). No
AEs led to patient withdrawal from the study. Overall,
the most commonly reported AEs were worsening of
RA, increase in alanine transferase, pyrexia, headache,
blood pressure increase and diarrhea. All AEs were
Grade 1, 2 or 3; there were no subjects with Grade 4 or
higher AEs.
There was no infusion reaction. SC injections of
GSK315234 did not cause any injection site related AEs.
There were more treatment-related AEs in the
GSK315234 treated patients (16/64, 25%) compared to
the placebo treated patients (0, 0%).
Non-fatal severe adverse events (SAEs) were reported
for two patients: breast cancer and acute sinusitis.
There was a dose related decrease in platelet number,
although all platelet counts were within the normal refe-
rence range. Percentage and mean changes from baseline
are detailed in Table 2 and Figure 3, respectively. These re-
ductions generally occurred around Day 19, appeared to
be dose dependent and resolved within two to four weeks.
This decrease in platelet count is consistent with the
pharmacology of GSK315234 and appeared to be doseTable 2 Total number of patients (%) with any adverse event
Adverse events numbe
(%)
Part Treatment group (N) Any AE Any AE
A 0.03/0.06 mg/kg IV (N = 4)a 2 (50) 1 (25)
0.3 mg/kg IV (N = 8)a 2 (25) 2 (25)
3 mg/kg IV (N = 12) 7 (58) 5 (42)
10 mg/kg IV (N = 12) 6 (50) 5 (42)
20 mg/kg IV (N = 6) 5 (83) 4 (67)
30 mg/kg IV (N = 6) 4 (67) 3 (50)
B 6 mg/kg repeat IV (N = 37) 15 (41) 8 (22)
C 500 mg SC (N = 12) 6 (50) 6 (50)
Pooled (Parts A, B, C) All Placebo (N = 38) 12 (32) 8 (21)
AE, adverse event; IV, intravenous patient; SC, subcutaneous patient.proportional with platelets demonstrating a greater de-
crease from baseline over a longer period of time.
Immunogenicity
Anti-GSK315234 antibodies were observed in about 25%
of patients at all dose levels except for the 0.3 mg/kg
and 20 mg/kg in which no anti-GSK315234 antibodies
were observed. Treatment failure did not relate to the
presence anti-GSK315234.
Pharmacokinetics and pharmacodynamics
After single and multiple IV infusion dosing, GSK315234
peak concentrations were achieved on average at two to
four hours after dosing. Following the peak, concentra-
tions declined slowly with a mean terminal t½ of about
300 to 400 hours after both single and repeat dosing. No
accumulation was observed after multiple IV infusions in
Part B, with the mean accumulation ratio being 1.08. An
exploratory PK/PD analysis showed some improvement in
DAS28 at lower exposures (doses ≤3 mg/kg), supported
by a significant effect on CRP and IL-6 (U-shape exposure-
response). One potential explanation for this data is mo-
derate to poor binding affinity (800 pM) and rapid off rate
of GSK315234 compared to the higher affinity OSM recep-
tor (150 pM) causing a protein carrier effect. This is
supported by synovial fluid data in which, although the
majority of the OSM is complexed, there was a significant
amount of free OSM present in the synovial fluid
(Figure 4).
Discussion
Administration of GSK315234 to patients with active
RA was expected to reduce signs and symptoms of RA
due to the effects of OSM on inflammation, pannus for-
mation, synovial cellular infiltrate and joint damage. The
results of this three-part, multicenter study show noand decrease in platelet
r of patients Percentage decrease in platelet number of patients
(%)
(days 1–28) 25 to 38% 39 to 51% 52 to 85% All
0 0 0 0
1 (13%) 0 0 1 (13%)
6 (50%) 0 0 6 (50%)
4 (33%) 0 1 (8%) 5 (42%)
2 (33%) 2 (33%) 0 4 (67%)
1 (17%) 2 (33%) 0 3 (50%)
10 (27%) 4 (11%) 1 (3%) 15 (41%)
5 (42%) 2 (17%) 0 7 (58%)
8 (21%) 1 (3%) 1 (3%) 10 (26%)
Figure 3 Mean percentage change in platelet count before and after treatment in Part A.
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the study. However, there is evidence of pharmacology
and downstream biologic effect with a dose dependent
decrease in platelets. The platelet reduction is not con-
sidered clinically significant or a safety related issue since
in all patients, platelet counts remained within the normal
range. OSM stimulates hepatocytes to release acute phase
reactants [16-18]. Anti-OSM mAb does not bind to IL6;
therefore, GSK315234 does not have a direct effect on the
































Study OSM104972 Part II B Res
and Total OSM
Figure 4 Free and Total oncostatin M in one patient following repeatbe due to inhibition of OSM and indirectly through reduc-
tion in disease activity.
In Part A, the single dose study showed a statistically
significant clinical response in the 3 mg/kg group on
Days 56 and 84 and the 10 mg/kg group on Day 84. One
potential explanation is that OSM is not a good thera-
peutic target in RA and the positive results in the single
dose study were false positives. Alternatively, if the ob-
servations that statistically significant changes in DAS28
compared to placebo occurred in the 3 mg/kg group onSM Synovial Fluid Total OSM Serum
ults, Synovial Fluid and Serum, Free 
: Subject 36505
Dose 2 Day 28
Dose 3 Day 28
2097pg/m
ing dosing with GSK315234.
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yet the effect on DAS28 scores at high doses (20 and 30
mg/kg) appeared to be worse compared with the low-
medium doses are true, it would suggest a U-shape re-
sponse curve. Such a response has been observed in
some medical conditions but not in clinical trials of
musculoskeletal diseases [19]. Inadequate neutralisation
of other cytokines due to a protein carrier effect has
been reported in the literature and included situations in
which there is a high target load, for example, IL-6 in can-
cer patients [20]. We conducted an exploratory PK/PD
analysis which showed some improvement in DAS28 at
lower exposures (doses ≤3 mg/kg), supported by a signifi-
cant effect in CRP and IL-6 (U-shape exposure-response).
One potential explanation is for a protein carrier effect
due to the moderate to poor binding affinity (2.14 nM
at 37°C by BiaCore) and rapid off-rate (1.73× 103) of
GSK315234 compared to the higher affinity OSM recep-
tor (150 pM) at the site of action in the synovial joint.
We hypothesize that GSK315234 binds to circulating
OSM. At low doses of GSK315234, it was unable to neu-
tralise OSM. At a moderate dose, GSK315234 effectively
neutralised the activity of OSM. At high doses of
GSK315234, all OSM will be complexed to GSK315234.
The GSK315234-OSM complex will have a longer half-
life than OSM. However, due to the high off rate and
low binding affinity of GSK315234 relative to the OSM
receptor, GSK315234 acts as a carrier of OSM and OSM
is released in the synovial joint. Our results suggest that
other factors, such as accumulation of the OSM com-
plex and rate of dissociation from GSK315234, need to
be properly considered (Figure 3).
Nevertheless, both single and repeat dosing with
GSK315234 was generally well tolerated. The PK/PD
analysis suggested that moderate affinity and rapid off
rate of GSK315234 may lead to a U-shape dose res-
ponse. A higher affinity anti-OSM antibody is needed to
truly examine the role of OSM in RA. It may also have
the potential to treat fibrotic lung disease based on
OSM biology [21].
Conclusion
Our data highlight the importance of binding affinity and
off-rate effect of a mAb to fully neutralize the target and
how this may influence its efficacy and potentially worsen
disease activity. Using an anti-OSM mAb with high affinity
should test this hypothesis and examine the potential of
OSM as a therapeutic target in RA.
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